Leerink cuts target for Bristol Myers Squibb stock to USD 59.00
Published on 10/06/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock stood at EUR 52.29 at Lang & Schwarz on October 6, 2026 at 11:33 a.m. CEST, down 0.25 percent from the EUR 52.42 prior close. According to Investing.com on October 5, 2026, Leerink Partners cut its target from USD 73.00 to USD 59.00 and changed its rating from Outperform to Market Perform.
Pipeline doubts drive the downgrade
The analyst action centers on three late-stage programs. Investing.com reports that Leerink raised concerns about efficacy or safety risks for admilparant, questioned milvexian against Eliquis in atrial fibrillation, and sees commercial adoption risks for Cobenfy in Alzheimer disease psychosis.
The target reduction is a USD 14.00 cut, or 19.18 percent versus the former USD 73.00 target. That calculation uses the two targets in the October 5, 2026 report and marks a materially more cautious view of Bristol Myers Squibb's pipeline contribution.
Results date adds a second catalyst
Investing.com states that Bristol Myers Squibb is scheduled to report third-quarter 2026 earnings on October 29, 2026. The date gives the market a defined checkpoint for revenue trends, operating performance and updates on the clinical pipeline.
Analyst expectations remain mixed rather than uniformly negative. In a September 25, 2026 overview, MarketBeat counted 25 brokerages, including 13 Buy ratings, 10 Hold ratings, one Sell rating and one Strong Buy rating. Its average 12-month target was USD 67.06, showing that the Leerink view sits below the broader published target range.
Stock remains below its recent high
Bristol Myers Squibb had a market capitalization of USD 120.1 billion and a 52-week range of USD 42.52 to USD 68.64 as of October 5, 2026. The Lang & Schwarz quote therefore sits EUR 0.13 below its prior close, while the primary-exchange context confirms the company as Bristol-Myers Squibb Company, ticker BMY, listed on the NYSE.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 6, 2026, 11:33 a.m. CEST): EUR 52.29
- Change versus prior close: minus 0.25 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 52.42
- Market capitalization: USD 120.1 billion (as of October 5, 2026)
- 52-week range: USD 42.52-68.64 (as of October 5, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
